Dosage of haloperidol for mania. 1994

A Rifkin, and S Doddi, and B Karajgi, and M Borenstein, and R Munne
Mount Sinai School of Medicine, New York.

BACKGROUND We compared three doses of a neuroleptic as a treatment for mania. METHODS Forty-seven newly admitted in-patients with mania were randomised to receive 10, 30, or 80 mg a day of oral haloperidol, under double-blind conditions for up to six weeks. All subjects received prophylactic benztropine. RESULTS Repeated-measures analysis of variance and survival analysis showed no difference in outcome by the different doses. Excluding drop-outs (38%), most of whom left the study during the first two weeks, 72% of the subjects responded. Side-effects were minimal; there were no differences among the three doses. Non-responders received more adjunctive lorazepam than responders. CONCLUSIONS The limited data suggest that more than 10 mg a day of haloperidol offers no advantage in mania.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009460 Neurologic Examination Assessment of sensory and motor responses and reflexes that is used to determine impairment of the nervous system. Examination, Neurologic,Neurological Examination,Examination, Neurological,Examinations, Neurologic,Examinations, Neurological,Neurologic Examinations,Neurological Examinations
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D005260 Female Females
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A Rifkin, and S Doddi, and B Karajgi, and M Borenstein, and R Munne
July 2006, The Cochrane database of systematic reviews,
A Rifkin, and S Doddi, and B Karajgi, and M Borenstein, and R Munne
January 1986, Drug intelligence & clinical pharmacy,
A Rifkin, and S Doddi, and B Karajgi, and M Borenstein, and R Munne
November 2004, The American journal of psychiatry,
A Rifkin, and S Doddi, and B Karajgi, and M Borenstein, and R Munne
November 2004, The American journal of psychiatry,
A Rifkin, and S Doddi, and B Karajgi, and M Borenstein, and R Munne
May 1962, The Journal of mental science,
A Rifkin, and S Doddi, and B Karajgi, and M Borenstein, and R Munne
July 1989, International clinical psychopharmacology,
A Rifkin, and S Doddi, and B Karajgi, and M Borenstein, and R Munne
August 2001, Journal of clinical psychopharmacology,
A Rifkin, and S Doddi, and B Karajgi, and M Borenstein, and R Munne
November 1968, The Practitioner,
A Rifkin, and S Doddi, and B Karajgi, and M Borenstein, and R Munne
September 1977, The British journal of psychiatry : the journal of mental science,
A Rifkin, and S Doddi, and B Karajgi, and M Borenstein, and R Munne
July 2000, Journal of affective disorders,
Copied contents to your clipboard!